Anbio Biotechnology (NASDAQ:NNNN) Sees Large Decrease in Short Interest

Anbio Biotechnology (NASDAQ:NNNN) was the target of a significant decrease in short interest in October. As of October 15th, there was short interest totaling 31,124 shares, a decrease of 42.4% from the September 30th total of 54,022 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average trading volume of 46,624 shares, the days-to-cover ratio is currently 0.7 days.

Anbio Biotechnology Stock Up 4.5%

NNNN stock traded up $0.15 during trading on Monday, reaching $3.51. 56,457 shares of the stock were exchanged, compared to its average volume of 77,166. The firm’s 50 day moving average is $5.47 and its 200 day moving average is $16.73. Anbio Biotechnology has a twelve month low of $3.09 and a twelve month high of $44.73.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Anbio Biotechnology from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, October 8th. One analyst has rated the stock with a Hold rating. According to MarketBeat.com, the company presently has a consensus rating of “Hold”.

About Anbio Biotechnology

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.